Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...

Founded by Wei Wang in 2013, Canoe has now raised a total of $25.0M in total equity funding and is backed by The Carlyle Group, F-Prime Capital, Hamilton Lane, Eight Roads Ventures, and Nasdaq ...

Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Ovarian Cancer.